capivasertib news

All news on capivasertib (also known as TRUQAP): plants, production capacities, investments and involved companies.

16 September 2026

Chugai: FoundationOne CDx approved as companion diagnostic for tovorafenib in BRAF‑altered/fusion glioma

Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.
12 June 2026

Roche VENTANA PTEN (SP218) FDA-cleared as PTEN companion diagnostic in prostate cancer

First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.

Who will be producing capivasertib in the future?

Find out with chemXplore

Learn more